Alzamend Neuro Reports Increased Net Losses and Operating Expenses for Three and Nine Months Ended January 31, 2026

Alzamend Neuro, Inc. reported its financial results for the three and nine months ended January 31, 2026, revealing a significant increase in operating expenses and net losses compared to the same period in the previous fiscal year. The company recorded a net loss of $2.2 million for the three months ended January 31, 2026, compared to a loss of $1.0 million for the same period in 2025, marking a 112% increase. For the nine-month period, the net loss was $5.9 million, up from $3.4 million in the prior year, reflecting a 75% increase. The company has not generated any revenue to date, as it remains focused on the clinical development of its two product candidates, AL001 and ALZN002.

Total operating expenses for the three months ended January 31, 2026, reached $2.2 million, a 112% increase from $1.0 million in the same period last year. This rise was primarily driven by a substantial increase in research and development expenses, which surged to $1.3 million from $447,000, largely due to costs associated with clinical trials. General and administrative expenses also increased to $919,000 from $590,000, reflecting higher professional fees and salaries. The company’s accumulated deficit as of January 31, 2026, stood at $64.4 million, with total stockholders' equity reported at $2.2 million.

In terms of operational developments, Alzamend Neuro has made strides in its clinical trials. The company completed a Phase IIA clinical trial for AL001 in November 2025, which is designed to treat Alzheimer’s disease, bipolar disorder, major depressive disorder, and post-traumatic stress disorder. The trial's positive topline data was announced in June 2023, and the company plans to initiate further clinical trials to evaluate the drug's efficacy. Additionally, Alzamend has partnered with Massachusetts General Hospital to conduct these trials, indicating a strategic move to enhance its clinical capabilities.

The company’s financial position has been impacted by its reliance on external funding, with cash reserves decreasing to $2.7 million as of January 31, 2026, down from $3.9 million at the end of the previous fiscal year. Alzamend has indicated that it will need to raise additional capital to support its ongoing operations and clinical development activities. The company plans to pursue funding through public equity, private equity, and debt financing. The management has expressed concerns about its ability to continue as a going concern if it cannot secure the necessary funding.

Looking ahead, Alzamend Neuro anticipates continuing to incur losses as it advances its clinical programs. The company is focused on optimizing the development of its product candidates and expanding its pipeline. However, the need for substantial additional funding remains a critical factor in its operational strategy, as the company aims to bring its innovative treatments to market while managing the financial challenges associated with clinical development.